Completed PHASE3 INTERVENTIONAL NCT00407056

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Severe Uveitis

Phase 3 Open-Labeled Study of 0.05% Difluprednate Ophthalmic Emulsion in the Treatment of Severe Anterior Uveitis (Including Panuveitis).

Sponsor: Sirion Therapeutics, Inc.

Conditions Panuveitis Uveitis

Interventions Difluprednate Ophthalmic Emulsion

Updated 4 times since 2017 Last updated: Nov 29, 2006 Started: Aug 31, 2002 Completion: Jun 30, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Panuveitis and Uveitis, this trial is completed. The trial is conducted by Sirion Therapeutics, Inc. and has accumulated 4 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Aug 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sirion Therapeutics, Inc.

Data source: Sirion Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.